FLT3 and acute myeloid leukemia: Following the detection of FLT3 and especially FLT3-ITD as a molecular marker in AML, larger cohorts of AML patients were studied to determine its prognostic value, and first efforts were made to establish a specific and targeted therapy against FLT3.